Table 4.
N-Cav2-20 | Cav19-40 | Cav68-80 | C-Cav161-178 | |||||
---|---|---|---|---|---|---|---|---|
Observed | Theoretical | Observed | Theoretical | Observed | Theoretical | Observed | Theoretical | |
Aqueous buffer | 21.7 ± 0.8 | 23.6 ± 2.6 | 23.8 ± 1.2 | 24.4 ± 0.6 | 24.2 ± 0.3 | 23.9 ± 0.7 | 25.0 ± 1.7* | 35.3 ± 1.6 |
50% TFE | 46.3 ± 7.2 | 47.6 ± 1.8 | 58.7 ± 7.7 | 56.3 ± 2.3 | 45.9 ± 2.8 | 49.8 ± 1.8 | 44.2 ± 10.6* | 67.8 ± 3.2 |
1 mM SUV | 34.7 ± 6.0 | 37.7 ± 1.9 | 37.7 ± 3.6 | 39.0 ± 2.3 | 31.3 ± 0.2* | 37.5 ± 1.9 | 51.9 ± 2.4 | 49.5 ± 6.2 |
NSP4112-140-Caveolin-1 Peptide-Peptide Interactions: Percent α-helical content of NSP4112-140 peptide + Caveolin-1 peptides, in aqueous buffer (10 mM potassium phosphate buffer), 50% trifluoroethanol (TFE) and in the presence of 1 mM SUV (55 : 35 : 10, POPC/cholesterol/DOPS). Observed values were compared with theoretical values, and those that were statistically significant by a Student's t-test (P < 0.05; denoted by an asterisk) were considered structurally altered, indicative of an interaction. Results are presented as means ± S.D. (n = 3 or 4).